Prot #GR44277: A Phase III, Multicenter, Randomized, Double‐Masked, Sham‐Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Uveitic Macular Edema

Project: Research project

Project Details

StatusActive
Effective start/end date7/18/23 → 6/15/25

Funding

  • Genentech, Inc (Prot #GR44277)